- Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURAGrohe, C.; Herbst, R. S.; Tsuboi, M.; John, T.; Majem, M.; Goldman, J. W.; Kim, S. -W.; Marmol, D.; Rukazenkov, Y.; Wu, Y. -L.; Engel-Riedel, W.
- Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).Herbst, Roy S.; Tsuboi, Masahiro; John, Tom; Kato, Terufumi; Majem, Margarita; Grohe, Christian; Wang, Jie; Goldman, Jonathan W.; Lu, Shun; Su, Wu-Chou; De Marinis, Filippo; Shepherd, Frances A.; Lee, Ki Hyeong; Le, Nhieu; Dechaphunkul, Arunee; Kowalski, Dariusz M.; Poole, Lynne; Stachowiak, Marta; Rukazenkov, Yuri; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 12
- Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated resultsLyu, C.; Fang, W.; Jiao, W.; Ma, H.; Wang, J.; Xu, S.; Wu, N.; Wang, R.; Yang, Y.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 7
会议论文
Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
52被引9阅读
